Comparison Arterial Blood Pressure and Cardiac Index-based Hemodynamic Management on Postoperative Myocardial Injury
Myocardial Injury, Perioperative/Postoperative Complications
About this trial
This is an interventional prevention trial for Myocardial Injury
Eligibility Criteria
Inclusion Criteria:
- Patients who will undergo pancreatic-hepatic surgery
- Patients over 65 years of age or patients over 45 years of age and with at least one of the following comorbidities:
coronary artery disease, Congestive heart failure, moderate to severe heart valve disease, peripheral artery disease Moderate to Severe Pulmonary hypertension, cerebrovascular accident older than 1 month, History of pulmonary embolism more than 1 month old, Diabetes Mellitus, Hypertension
Exclusion Criteria:
- Presence of atrial fibrillation, sepsis, pulmonary embolism
- Presence of pulmonary embolism, acute coronary syndrome and cerebrovascular accident in the last month
- Static respiratory system compliance < 35ml/cmH2O
- Patients with preoperative high sensitive Troponin T value >65ng/liter
- glomerular filtration rate < 60 ml/min
Exclusion criteria during the protocol:
- Newly developed arrhythmia, embolism, sepsis,
- Cancellation of planned surgery
- Postoperative hepatic failure defined as INR>2
Sites / Locations
- Başakşehir Çam and Sakura City Hospital
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Mean Arterial Pressure (MAP) Group
Cardiac Index (CI) Group
Target MAP: Baseline MAP +/- 20% and MAP>65mmHg Baseline MAP: MAP average in the ward at rest the day before surgery Low MAP intervention If PPV>14, apply 500ml crystalloid If PPV>9 and any additional finding regarding hypovolemia, apply 500ml crystalloid If PPV<10, start/titrate noradrenaline infusion
CI: Baseline CI +/- 20% and CI > 2.2 L/m2/min Baseline CI: CI calculated by MostCare monitor before the anesthesia induction starts Low CI intervention If PPV>9, apply mini fluid challenge (MFC). If MFC is positive, apply 500ml crystalloid. If MFC is negative, evaluate MAP. If MAP is elevated start/titrate remifentanil. If MAP is not elevated start/titrate dopamine/dobutamine in accordance with systemic vascular resistance index (SVRI)